Triple gene-deleted oncolytic herpes simplex virus vector double-armed with interleukin 18 and soluble B7-1 constructed by bacterial artificial chromosome-mediated system

Cancer Research

Volumn 65, Issue 23, 2005, Pages 10663-10668

  Fukuhara, Hiroshi ^a,b   Ino, Yasushi ^a,b   Kuroda, Toshihiko ^a   Martuza, Robert L ^a   Todo, Tomoki ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

B7 1 ANTIBODY; B7 ANTIGEN; CRE RECOMBINASE; GENE PRODUCT; HERPESVIRUS VECTOR; IMMUNOGLOBULIN; INTERLEUKIN 18; LOXP RECOMBINASE; ONCOLYTIC VIRUS; PROTEIN G47DELTA; RECOMBINASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BACTERIAL ARTIFICIAL CHROMOSOME; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; DRUG EFFICACY; DRUG SAFETY; FEMALE; GENE DELETION; GENE INSERTION; GENE LOCUS; GENE MUTATION; HERPES SIMPLEX VIRUS 1; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LOXP SITE; MALE; MOUSE; NEUROBLASTOMA CELL; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; T LYMPHOCYTE; TRANSGENE; VIRUS GENOME; VIRUS RECOMBINANT;

ANIMALS; ANTIGENS, CD80; CERCOPITHECUS AETHIOPS; CHROMOSOMES, ARTIFICIAL, BACTERIAL; GENE DELETION; GENETIC VECTORS; HERPESVIRUS 1, HUMAN; INTERLEUKIN-18; MALE; MICE; MICE, INBRED A; MICE, INBRED C57BL; NEUROBLASTOMA; ONCOLYTIC VIROTHERAPY; PROSTATIC NEOPLASMS; RECOMBINASES; TRANSFECTION; VERO CELLS;

EID: 28244502278     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-2534     Document Type: Article

References (19)

1. Markert JM, Medlock MD, Rabkin SD, et al. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther 2000;7:867-74.
2. Mineta T, Rabkin SD, Yazaki T, Hunter WD, Martuza RL. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med 1995;1:938-43.
3. Todo T, Martuza RL, Rabkin SD, Johnson PA. Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing. Proc Natl Acad Sci U S A 2001;98:6396-401.
4. Todo T, Rabkin SD, Sundaresan P, et al. Systemic antitumor immunity in experimental brain tumor therapy using a multimutated, replication-competent herpes simplex virus. Hum Gene Ther 1999;10:2741-55.
5. Todo T, Martuza RL, Dallman MJ, Rabkin SD. In situ expression of soluble B7-1 in the context of oncolytic herpes simplex virus induces potent antitumor immunity. Cancer Res 2001;61:153-61.
6. Saeki Y, Breakefield XO, Chiocca EA. Improved HSV-1 amplicon packaging system using ICP27-deleted, oversized HSV-1 BAC DNA. Methods Mol Med 2003;76:51-60.
7. Saeki Y, Ichikawa T, Saeki A, et al. Herpes simplex virus type 1 DNA amplified as bacterial artificial chromosome in Escherichia coli: rescue of replication-competent virus progeny and packaging of amplicon vectors. Hum Gene Ther 1993;9:2787-94.
8. Stavropoulos TA, Strathdee CA. An enhanced packaging system for helper-dependent herpes simplex virus vectors. J Virol 1998;72:7137-43.
9. Horsburgh BC, Hubinette MM, Qiang D, MacDonald ML, Tufaro F. Allele replacement: an application that permits rapid manipulation of herpes simplex virus type 1 genomes. Gene Ther 1999;6:922-30.
10. Suter M, Lew AM, Grob P, et al. BAC-VAC, a novel generation of (DNA) vaccines: a bacterial artificial chromosome (BAC) containing a replication-competent, packaging-defective virus genome induces protective immunity against herpes simplex virus 1. Proc Natl Acad Sci U S A 1999;96:12697-702.
11. Kambara H, Okano H, Chiocca EA, Saeki Y. An oncolytic HSV-1 mutant expressing ICP34.5 under control of a nestin promoter increases survival of animals even when symptomatic from a brain tumor. Cancer Res 2005;65:2832-9.
12. Bennett JJ, Malhotra S, Wong RJ, et al. Interleukin 12 secretion enhances antitumor efficacy of oncolytic herpes simplex viral therapy for colorectal cancer. Ann Surg 2001;233:819-26.
13. Liu BL, Robinson M, Han ZQ, et al. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Ther 2003;10:292-303.
14. Hura S, Nagai H, Miyake H, et al. Secreted type of modified inrerleukin-18 gene transduced into mouse renal cell carcinoma cells induces systemic tumor immunity. J Urol 2001;165:2039-43.
15. Logvinoff C, Epstein AL. A novel approach for herpes simplex virus type 1 amplicon vector production, using the Cre-loxP recombination system to remove helper virus. Hum Gene Ther 2001;12:161-7.
16. Buchholz F, Angrand PO, Stewart AF. Improved properties of FLP recombinase evolved by cycling mutagenesis. Nat Biotechnol 1998;16:657-62.
17. Umana P, Gerdes CA, Stone D, et al. Efficient FLPe recombinase enables scalable production of helper-dependent adenoviral vectors with negligible helper-virus contamination. Nat Biotechnol 2001;19:582-5.
18. Goto H, Yang B, Petersen D, et al. Transduction of green fluorescent protein increased oxidative stress and enhanced sensitivity to cytotoxic drugs in neuroblastoma cell lines. Mol Cancer Ther 2003;2:911-7.
19. Gambotto A, Dworacki G, Cicinnati V, et al. Immunogenicity of enhanced green fluorescent protein (EGFP) in BALB/c mice: identification of an H2-Kd-restricted CTL epitope. Gene Ther 2000;7:2036-40.